Signify Bio

Signify Bio, based in the US, develops personalized medicines focusing on nucleic acid-enabled protein therapeutics to address genetic and acquired diseases. Signify Bio focuses on the development of personalized medicines through advanced biotechnological approaches. The company was founded in Dallas, US in 2024 by Lukas Farbiak and RA Session, who also serves as the CEO. The company raised USD 15.

00 mn in a funding round led by Actium Group on June 5, 2025, which marked the total amount raised since inception. It has engaged in 1 deal to date, primarily targeting pharmaceutical and research organizations for collaboration. Signify Bio specializes in developing personalized medicines with a focus on nucleic acid-enabled protein therapeutics. Their core offerings leverage advanced biotechnological approaches to create tailored treatments aimed at addressing various genetic and acquired diseases.

The company’s products are designed to optimize therapeutic efficacy and safety profiles, reflecting a commitment to enhancing patient outcomes. Target customers include healthcare providers, research institutions, and pharmaceutical companies, which utilize Signify Bio's solutions in clinical settings and drug development initiatives. The company operates in multiple geographical markets, with a notable presence in North America, Europe, and parts of Asia, where it caters to a diverse clientele engaged in medical research and treatment applications. Signify Bio generates revenue through strategic partnerships and collaborations in the biotechnology sector, focusing on B2B transactions with pharmaceutical and research organizations.

The company typically engages in contractual agreements that outline shared responsibilities for development and commercialization of its product offerings. These partnerships may involve milestone payments and royalties based on the sales performance of the therapeutic products developed collaboratively. The company’s revenue model is enhanced by its flagship nucleic acid-enabled therapeutics, which are integral to its offerings and are expected to drive market adoption among its clients. Pricing plans are structured around the value delivered through these therapies, aligning with client needs and market dynamics.

In June 2025, Signify Bio raised USD 15. 00 mn in venture funding led by Actium Group, with participation from the Bill & Melinda Gates Foundation Trust, Danaher Corporate Development/Ventures, Eli Lilly and Company, and BrightEdge Ventures. The company will use the funding to expand R&D to accelerate the development of in situ protein therapeutics and expand its operations. This initiative is part of a broader strategy to introduce new products aimed at addressing unmet medical needs and to enhance its presence in global markets.